跳至主要内容
临床试验/NCT04615611
NCT04615611Unknown不适用

Individual beta2-adrenergic Performance Response to Salbutamol

University of Copenhagen0 个研究点目标入组 20 人开始时间: 2020年11月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
20
主要终点
Sprint performance

研究概览

简要总结

This project aims to investigate the individual physiological response to beta2-adrenergic stimulation with salbutamol on performance-related outcomes

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 18 to 45 years of age
  • Trained individuals with maximal oxygen uptake above 55 mL/kg/min for men and 50 mL/kg/min for women
  • Body mass index lower than 26

排除标准

  • Allergy towards study drug
  • Unacceptable side effects of the study drug
  • Chronic disease deemed by the MD to impose a risk or severely confound the study outcomes
  • Current smokers
  • Use of prescription medicine
  • Pregnancy

研究组 & 干预措施

salbutamol

Experimental

salbutamol, 800 microgram from metered dose inhaler

干预措施: salbutamol (Drug)

placebo

Placebo Comparator

placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Sprint performance

时间窗: Measured ½ hour after drug administration

Power output during maximal cycling

次要结局

  • Cycling endurance performance(Measured ½ hour after drug administration)
  • Muscle strength(Measured ½ hour after drug administration)
  • Sprint fatigue tolerance(Measured ½ hour after drug administration)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Morten Hostrup, PhD

Associate Professor

University of Copenhagen

相似试验

Physiologic Performance Response to Salbutamol | 临床试验